Preclinical experiments on cognition enhancement in Alzheimer's disease: Drugs affecting nicotinic acetylcholine receptors

Drug Development Research

Volumn 56, Issue 3, 2002, Pages 335-346

  Woodruff Pak, Diana S ^a,b  

^a TEMPLE UNIVERSITY   (United States)

^b EINSTEIN MEDICAL CENTER   (United States)

Author keywords

Acetylcholine; Acetylcholinesterase inhibition; Allosteric modulation; Dementia; Eyeblink classical conditioning; Learning; Memory; Nicotinic acetylcholine receptors (nAChRs), 7 nAChR agonism or antagonism, normal aging

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE INHIBITOR; GALANTAMINE; NEFIRACETAM; NICOTINIC AGENT; NICOTINIC RECEPTOR; NOOTROPIC AGENT;

ALLOSTERISM; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; CONDITIONING; DRUG EFFICACY; EYELID REFLEX; HUMAN; MEMORY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; RABBIT; REVIEW; STATE DEPENDENT LEARNING;

EID: 0036659998     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10086     Document Type: Review

References (98)

1. Auld DS, Kar S, Quirion R. 1998. Beta-amyloid peptides as direct cholinergic neuromodulators. A missing link? TINS 21:43-49.
2. 3H-mecamylamine binding and the brain nicotinicreceptor. Soc Neurosci Abst.16:1143.
3. Bartus RT. 2000. On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten following the cholinergic hypothesis. Exp Neurol 163:495-529.
4. Bartus RT, Dean RL, Beer B. Lippa AS 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-417.
5. Blaxton TA, Zeffiro TA, Gabrieli JDE, Bookheimer SY, Carrillo MC, Theodore WH, Disterhoft JF. 1996. Functional mapping of human learning: a positron-emission tomography study of eyeblink conditioning. J Neurosci 16:4032-4040.
6. Bowen DM, Smith CB, White P, Davison AN. 1976. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99:459-496.
7. Conroy WG, Vernallis AB, Berg DK. 1992. The α5 gene product assembles with multiple acetylcholine receptor subunits to form distinctive receptor subtypes in brain. Neuron 9:679-691.
8. Cooper E, Couturier S, Ballivet M. 1991. Pentameric structure and subunit stoichiometry of a neuronal acetylcholine receptor. Nature 350:235-238.
9. Court JA, Perry EK. 1995. Distribution of nicotinic receptors in the CNS. In: Stone TW, editor. CNS neurotransmitters and neuromodulators. London: CRC Press. p 85-104.
10. Couturier S, Bertrand D, Matter JM, Hernandez MC, Bertrand S, Millar N, Valera S, Barkas T, Ballivet M. 1990. A neuronal nicotinic acetylcholine receptor subunit (α7) is developmentally regulated and forms a homo-oligomeric channel blocked by α-BTX. Neuron 5:847-856.
11. Coyle JT, Price DL, DeLong MR. 1983. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 219:1184-1190.
12. Daum I, Sehugens MM, Breitenstein C, Topka H, Spieker S. 1996. Classical eyeblink conditioning in Parkinson's disease. Mov Disord 11:639-646.
13. Davies P, Maloney AJF. 1976. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403.
14. 125-α-bungarotoxinreceptor subtypes. Mol Pharmacol 47:164-171.
15. Deutsch JA, Hamburg MD, Dahl H. 1966. Anticholinesterase induced amnesia and its temporal aspects. Science 151:221-223.
16. Dineley KT, Westerman M, Bui D, Beli K, Ashe KH, Sweatt JD. 2001. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21:4125-4133.
17. Frazier CJ, Buhler AV, Weiner JL, Dunwiddie TV 1998. Synaptic potentials mediated via α-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J Neurosci 18:8228-8235.
18. Funk KF, Schmidt J. Changes of dopamine metabolism by hypoxia and effect of nootropic drugs. Biomed Biochem Acta 1984;11:1301-1304.
19. Gould TJ, Wehner JW. 1999. Nicotine enhancement of contextual fear conditioning is specific for the contextual association but not the CS-US association. Behav Brain Res 102:31-39.
20. Gould TJ,Collins AC, Wehner JW. 2001. Nicotine enhances latent inhibition and ameliorates ethanol-induced deficits in latent inhibition. Nicotine Tob Res 1:17-24.
21. Green JT, Woodruff-Pak DS. 2000. Eyeblink classical conditioning in aging animals, In: Woodruff-Pak DS, Steinmetz JE, editors. Eyeblink classical conditioning: Volume II, Animal models. Boston: Kluwer. p 155-178.
22. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D. 1999. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenillin-1 mutations: Lack of association with amyloid deposits. Behav Genet 29:177-185.
23. Holliday MW, Dart MJ, Lynch JK. 1997. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Disc 40:4169-4194.
24. Kem WR, Abbott BC, Coates RM. 1971. Isolation and structure of a hoplonemertine toxin. Toxicol 9:15-22.
25. Kem WR, Mahnir VM, Papke RL, Lingle CJ. 1997. Anabaseine is a potent agonist on muscle and neuronal αbungarotoxin-sensitive nicotinic receptors. J Pharmacol Exp Ther 283:979-992.
26. Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, Akaike A. 1997. Nicotinic receptor stimulation protects neurons against β-amyloid toxicity. Ann Neurol 42:159-163.
27. Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, Akaike A. 1998. Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res 792:331-334.
28. Lee VM.-Y, Balin BJ, Otvos L Jr, Trojanowsld JQ 1991. A68: A major subunit of paired helical filaments and derivatized forms of normal tau. Science 251:675-678.
29. Lemieux SK, Woodruff-Pak DS, 1000. Functional MRI studies of eyeblink classical conditioning. In: Woodruff-Pak DS and Steinmetz JE, editors. Eyeblink classical conditioning Volume I: Applications in humans, Boston:Kluwer Academic Publishers. p 71-93.
30. Levin ED. 1992. Nicotinic systems and cognitive function. Psychopharmacol 108:417-431.
31. Lindstrom J. 1996. Neuronal nicotinic acetylcholine receptors. Ion Chan 4:377-450.
32. Lindstrom J, Schoepfer R, Conroy W, Whiting P, Das M, Saedi M, Anand R. 1991. The nicotinic acetylcholine receptor gene family: Structure of nicotinic receptors from muscle and neurons and neuronal α-bungarotoxin-binding proteins. Adv Exp Med Biol 287:255-278.
33. Lindstrom J, Anand R, Peng X, Gerzanich V, Wang F, Li Y. 1995 Neuronal nicotinic receptor subtypes. Ann NY Acad Sci 757:100-116.
34. Liu Q.-S, Kawai H, Berg DK, 2001. β-amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons, Proc Nat Acad Sci USA 98:4734-4739.
35. Logan CG, Grafton ST, 1995. Functional anatomy of human eyeblink classical conditioning determined with regional cerebral glucose metabolism and positron-emission topography. Proc Nat Acad Sci USA 92:7500-7504.
36. London ED, Ball MJ Waller SB. 1989. Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia. Neurochem Res 14:745-750.
37. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwin J, Albuquerque EX, Zerlin M. 2001. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psych 49:279-288.
38. Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX. 2000. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 113:199-206.
39. Marchi M, Besana E, Raiteri M. 1990. Oxiracetam increases the release of endogenous glutamate from depolarized rat hippocampal slices. Eur J Pharmacol 185:247-249.
40. Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, Tsouloufis T, Tzartos S, Ballard C, Perry RH, Perry EK. 1999. α4 but not α3 and α7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem 73:1635-1640.
41. Marutle A, Warpman U, Bognanovic N, Lannfelt L, Nordberg A. 1999. Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor 670/671 mutation. J Neurochem 72:1161-1169.
42. McGehee DS, Role LW. 1995. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Ann Rev Physiol 57:521-546.
43. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. 1995. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 269:1692-1696.
44. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Van Den Haute C, Cheeler F, Godaux E, Cordell B, Van Leuven F. 1999. Eary phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274:6483-6492.
45. Molchan SE, Sunderland T, McIntosh AR, Herscovitch P, Schreurs BG. 1994. A functional anatomical study of associative learning in humans. Proc Nat Acad Sci USA 91:8122-8126.
46. Moore JW, Goodell NA, Solomon PR. 1976.Central cholinergic blockade by scopolamine and habituation, classical conditioning, and latent inhibition of the rabbit's nictitating membrane response. Physiol Psychol 4:395-399.
47. Mullan J, Crawford F, Axelman K, Houlden H, Lillius L, Winblad B. 1992. A pathogenic mutation for probably Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nat Genet 1:345-347.
48. Nabeshima T, Noda Y, Tohyama K, Itoh J, Kameyama T. 1990. Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal dysfunctions. Eur J Pharmacol 178:143-149.
49. Newhouse PA, Kelton M. 2000. Clinical aspects of nicotinic agents: Therapeutic application in central nervous system disorders. In: Clementi F, Fornasari D, Gotti C, editors. Neuronal nicotinic receptors: experimental pharmacology, Vol. 14. Berlin: Springer. p 779-812.
50. Nishizaki T, Nomura T, Matuoka T, Kondoh T, Enikolopo G, Sumikawa K, Watabe S, Shiotani T, Yoshii M. 2000. The antidementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors, Mol Brain Res 80:53-62.
51. Nordberg A. 2001. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol Psych 49:200-210.
52. Nordberg A, Winblad B. 1986. Reduced number of 3H-nicotine and 3H-acetylcholine binding sites in the frontal cortex of Alzheimer's brains. Neurosci Lett 12:115-119.
53. 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J Neural Transm 2:215-224.
54. Olpe H-R, Lynch GS. 1982. The action of piracetam on the electrical activity of the hippocampal slice preparation: a field potential analysis. Eur J Pharmacol 80:415-419.
55. Pak JT, Green JT, Heifetz B, Pak MH, Woodruff-Pak DS. 2002. Nefiracetam ameliorates associative learning impairment in the scopolamine-injected older rabbit. Med Sci Monitor 8:105-112.
56. Papka M, Simon EW, Woodruff-Pak DS. 1994. A one-year longitudinal investigation of eyeblink classical conditioning and cognitive and behavioral tests in adults with Down's syndrome. Aging Cognition 1:89-104.
57. Papke RL, Sanberg PR, Shytle RD 2001 Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J Pharmacol Exp Ther 297:646-656.
58. Pereira EFR, Alkondon M, Reinhardt S, Maelicke A, Peng X, Lindstrom J, Whiting P, Albuquerque EX. 1994. Physostigmine and galantamine: probes for a novel binding site on the α4β2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J Pharmacol Exp Ther 270:768-778.
59. Pereira EFR, Reinhardt-Maelicke S, Schrattenholz A, Maelicke A, Albuquerque EX. 1993. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J PharmacoI Exp Ther 265:1474-1491.
60. Perry EK, Perry RH, Blessed G, Tomlinson BE. 1977. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1:189.
61. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. 1999. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303-314.
62. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Commings JL, DeKosky ST. 2001. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Neurology 56:1133-1142.
63. 1-42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 21:1-5.
64. Ramnani N, Toni I, Josephs J, Ashburner J, Passingham RE. 2000. Learning- and expectation-related changes in the human brain during motor learning. J Neurophysiol 84:3026-3035.
65. Sahakian BJ, Coull JT 1994. Nicotine and tetrahydroaminoacradine: evidence for improved attention in patients with dementia of the Alzheimer type. Drug Dev Res 31:80-88.
66. Satoh M, Ishihara K, Iwama T, Takagi H. 1986. Aniracetam augments, and midazolam inhibits, the long-term potentiation in guinea pig hippocampal slices. Neurosci Lett 68:216-220.
67. Schoepfer R, Conroy W, Whiting P, Gore M, Lindstrom J. 1990. Brain α-bungarotoxin-binding protein cDNAs and mAbs reveal subtypes of this branch of the ligand-gated ion channel gene superfamily. Neuron 5:35-48.
68. Schroder G, Giacobini E, Struble RG, Zilles K, Maelicke A. 1991. Nicotinic cholinergic receptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol Aging 12:259-262.
69. Selkoe DJ. 1999. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature, 399:A23-A31.
70. Shimohama S. Kihara T 2001. Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity. Biol Psych 49:233-239.
71. Solomon PR, Gottfried KE. 1981. The septo-hippocampal choliner gic system and classical conditioning of the rabbit's nictitating membrane response. J Comp Physiol Psychol 95:322-330.
72. Solomon PR, Solomon SD, Vander Schaaf E, Perry HE. 1983. Altered activity in the hippocampus is more detrimental to classical conditioning than removing the structure. Science 220:329-331.
73. Solomon PR, Levine E, Bein T, Pendlebury WW. 1991. Disruption of classical conditioning in patients with Alzheimer's disease. Neurobiol Aging 12:283-287.
74. Solomon PR, Brett M, Groccia-Ellison M, Oyler C, Tomasi M, Pendlebury WW. 1995. Classical conditioning in patients with Alzheimer's disease: a multiday study. Psychol Aging 10:248-254.
75. Spignoli G, Pepeu G. 1987. Interactions between oxiracetam, quaniracetam, and scopolamine on behavior and brain acetylcholine. Pharmacol Biochem Behav 27:491-495.
76. Steinmetz JE. 1996. The brain substrates of classical eyeblink conditioning in rabbits. In: Bloedel JR, Ebner TJ, Wise SP, editors. The acquisition of motor behavior in vertebrates. Cambridge, MA: MIT Press. p 89-114,
77. Storch A, Schrattenholz A, Cooper JC, Abdel Ghani M, Gutbrod O, Weber K.-H, Reinhardt S, Lobron C, Hermsen B, Soskic V, Pereira EFR, Albuquerque EX, Methfessel C, Maelicke A. 1995. Physostigmine, galanthamine and codeine act as non-competitive nicotinic agonists on clonal rat pheochromocytoma cells. Eur J Pharmacol 290:207-219.
78. Thompson RF. 2000. Discovering the brain substrates of eyeblink classical conditioning. In: Woodruff-Pak DS, Steinmetz JE, editors. Eyeblink classical conditioning: Volume II: Animal models. Boston: Kluwer Academic Publishers. p 17-49.
79. Thompson RF, Krupa DJ. 1994. Organization of memory traces in the mammalian brain. Ann Rev Neurosci 17:519-549.
80. Wang HY, Lee DH, Davis CB, Shank RP. 2000. Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 75:1155-1161.
81. Wevers A, Burghaus L, Moser N, Witter B, Steinlein OK, Schutz U, Achnitz B, Krempel U, Jansen Steur ENH, Schroder H. 2000. Expression of nicotinic acetylcholine receptors in Alzheimer's disease: postmortem investigations and experimental approaches. Behav Brain Res 113:207-215.
82. Woodruff-Pak DS. 1995. Evaluation of cognition-enhancing drugs: Utility of the model system of eyeblink classical conditioning. CNS Drug Rev 1:107-128.
83. Woodruff-Pak DS. 2001. Eyeblink classical conditioning differentiates normal aging from Alzheimer's disease. Integrative Physiol Behav Sci 36:87-108.
84. Woodruff-Pak DS, Hinchliffe RM. 1997. Scopolamine- or mecamylamine-induced learning impairment: reversed by nefiracetam. Psychopharmacology 131:130-139.
85. Woodruff-Pak DS, Papka M. 1996. Huntington's disease and eyeblink classical conditioning: Normal learning but abnormal timing. J Int Neuropsychol Soc 2:323-334.
86. Woodruff-Pak DS, Santos I. 2000. Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease. Behav Brain Res 113:11-19.
87. Woodruff DS, Finkbiner RG, Katz IR. 1989. A model system demonstrating parallels in animal and human aging: extension to Alzheimer's disease. In: Meyer EM, Simpkins JW, Yamamoto J, editors. Novel approaches to the treatment of Alzheimer's disease. New York: Plenum Press. p. 355-371.
88. Woodruff-Pak DS, Finkbiner RG, Sasse DK, 1990. Eyeblink conditioning discriminates Alzheimer's patients from non-demented aged. NeuroReport 1:45-49.
89. Woodruff-Pak DS, Li Y-T. 1994. Nefiracetam (DM-9384): effect on classical conditioning in older rabbits. Psychopharmacology 114:200-208.
90. Woodruff-Pak DS, Li Y-T, Kazmi A, Kem WR. 1994a. Nicotinic cholinergic system involvement of eyeblink classical conditioning in rabbits. Behav Neurosci 108:486-493.
91. Woodruff-Pak DS, Li Y-T, Kem WR. 1994b. A nicotinic agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res 645:309-317.
92. Woodruff-Pak DS, Papka M, Simon EW. 1994c. Eyeblink classical conditioning in Down's Syndrome, Fragile X Syndrome, and normal adults over and under age 35. Neuropsychol 8:14-24.
93. Woodruff-Pak DS, Papka M, Romano S, Li Y-T. 1996a. Eyeblink classical conditioning in Alzheimer's disease and cerebrovascular dementia. Neurobiol Aging 17:505-512.
94. Woodruff-Pak DS, Romano S, Papka M. 1996b. Training to criterion in eyeblink classical conditioning in Alzheimer's disease, Down's syndrome with Alzheimer's disease, and healthy elderly. Behav Neurosci 110:22-29.
95. Woodruff-Pak DS, Li Y-T, Hinchcliffe RM, Port RL. 1997. Hippocampus in delay eyeblink classical conditioning: essential for nefiracetam of learning in older rabbits. Brain Res 747:207-218.
96. Woodruff-Pak DS, Green JT, Coleman-Valencia C, Pak JT. 2000. A nicotinic cholinergic drug (GTS-21) and eyeblink classical conditioning: acquisition, retention, and relearning in older rabbits. Exp Aging Res 26;323-336.
97. Woodruff-Pak DS, Vogel RW III, Wenk GL. 2001. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci USA 98:2089-2094.
98. 2+ channels and nicotinic ACh receptors as functional targets of the nootropic nefiracetam. Psychogeriat 1:2-10.